Skip to main content

Azor FDA Approval History

FDA Approved: Yes (First approved September 26, 2007)
Brand name: Azor
Generic name: amlodipine and olmesartan
Dosage form: Tablets
Previous Name: amlodipine and olmesartan
Company: Daiichi Sankyo, Inc.
Treatment for: High Blood Pressure

Azor is a fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil. Azor is indicated for the treatment of hypertension.

Development timeline for Azor

May 13, 2009Approval Azor Receives FDA Approval as First-Line Treatment for High Blood Pressure
Sep 17, 2008Daiichi Sankyo, Inc. Files Supplemental New Drug Application for Azor as Initial Therapy for High Blood Pressure
Sep 27, 2007Approval Azor Receives FDA Approval for Treatment of High Blood Pressure
Aug 21, 2007Daiichi Sankyo and Forest Laboratories Sign Letter of Intent forCo-Promotion of Azor
Nov 28, 2006Daiichi Sankyo, Inc. Announces Filing of NDA for Amlodipine Besylate / Olmesartan Medoxomil Combination for the Treatment of Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.